Malignant Muscle Tissue Tumor in Dogs (Rhabdomyosarcoma of the Musculature)

  • Occurrence: rarer
  • Location of disease: General/Whole body
Author: Dr. med. vet. Gisa Löwe | Last modified: 24.08.2026
Open table of contents

When to visit the vet?

Non-urgent see a veterinarian within 2–3 days

?

If the condition worsens / symptoms persist, consult a veterinarian.

Download/Print

Definition

Rhabdomyosarcoma is a rare form of soft tissue cancer that develops in the musculature of dogs. This type of tumor is malignant and can spread quickly, making early diagnosis and treatment crucial.

The most important facts at a glance

Rhabdomyosarcomas are malignant Tumors that arise from the cells responsible for the formation of muscle tissue. These Tumors are aggressive and can spread to various parts of the body. Although rare in dogs, they represent a serious health problem. The exact causes of their development are not fully understood, but genetic and possibly environmental factors play a role. Common Symptoms include soft, diffuse masses in the musculature, Muscle weakness, and Lameness. A diagnosis requires a thorough examination, often imaging techniques, and a biopsy of the tumor.

The treatment of rhabdomyosarcomas is complex and usually involves a combination of surgery, radiation therapy, and chemotherapy. Surgical removal of the tumor is often the first choice, followed by further therapies to combat remaining tumor cells. The prognosis depends on many factors, including the size and location of the tumor, as well as the presence of metastases. Despite intensive treatment, there is a significant recurrence risk. Preventive measures are limited, but a healthy lifestyle and regular veterinary examinations can help promote the dog’s general well-being and detect potential health problems early.

Causes

Rhabdomyosarcomas arise from mesenchymal cells responsible for the formation of muscle tissue. These Tumors are malignant, meaning they can invade surrounding tissue and spread to other parts of the body. The exact origin of these Tumors is not yet fully understood, but they appear to arise from cells that were maldeveloped during embryogenesis.

While rhabdomyosarcomas are rare in dogs, they still pose a significant problem because they are aggressive and have a poor prognosis. The Tumors can occur in various muscles of the body, but most commonly in the muscles of the limbs or head. There are different subtypes of rhabdomyosarcomas, including embryonal, alveolar, and pleomorphic types, each of which can have different characteristics and courses.

The causes of rhabdomyosarcoma development in dogs are not fully understood. Genetic factors likely play a role, as an increased predisposition is observed in some dog breeds. Environmental factors and exposure to certain chemicals could also contribute to the development of these Tumors, although this has not yet been conclusively proven.

Genetic mutations occurring in tumor cells are frequently associated with the development of rhabdomyosarcomas. These mutations can occur spontaneously or be triggered by external factors. Studies suggest that certain genetic anomalies such as chromosomal aberrations and gene fusions may play a role in the development of these Tumors.

Symptoms

Rare symptoms:

The symptoms of rhabdomyosarcomas in dogs depend largely on the location and size of the tumor. Common signs are Swelling or lumps that are palpable under the skin, particularly near the limbs or on the head. These lumps may or may not be painful, depending on whether they press on nerves or other sensitive tissue.

Further Symptoms can include Lameness or difficulty moving, especially if the tumor is located near the joints or limbs. Dogs may also show signs of general malaise, loss of appetite, or Weight loss, especially if the tumor progresses and spreads to other body parts.

In advanced stages, systemic Symptoms such as Lethargy, weakness, and anemia may occur, as the tumor consumes the body’s resources or impairs blood formation. Respiratory distress can occur if the tumor presses on the airways or if metastases develop in the lungs.

Therapy

The treatment of rhabdomyosarcomas in dogs is complex and often requires a multimodal approach. Surgical removal of the tumor is usually the first treatment option, especially when the tumor is well-defined and resectable. The goal of surgery is to completely remove the tumor to minimize the risk of recurrence.

In addition to surgery, radiation therapy can be used, primarily if the tumor could not be completely removed or is located in a difficult-to-access area. Radiation therapy can help kill remaining tumor cells and control tumor growth.

Chemotherapy may also be part of the treatment plan, especially for aggressive or metastatic tumors. Various chemotherapy agents can be used to inhibit tumor growth and improve the dog’s quality of life. The choice of medications depends on the type of rhabdomyosarcoma and the dog’s overall health condition.

Prognosis and follow-up care

The prognosis for dogs with rhabdomyosarcoma varies widely and depends on several factors, including the size and location of the tumor, the presence of metastases, and the response to treatment. In general, the prognosis is better with early diagnosis and aggressive therapy.

However, rhabdomyosarcomas are often difficult to treat because they tend to grow quickly and spread rapidly. Even with combined treatment of surgery, radiation therapy, and chemotherapy, there is a significant risk of recurrence or the development of metastases.

The average survival time after diagnosis varies but can be several months to a year or longer with successful treatment. Close follow-up care is crucial to detect possible relapses early and take appropriate action.

Prevention

Since the exact causes of rhabdomyosarcomas are not fully understood, there are no specific preventive measures to prevent these tumors in dogs. However, general health care and regular veterinary examinations can help detect potential health problems early.

A balanced diet, regular exercise, and a healthy lifestyle can help promote the dog’s overall well-being and health, potentially reducing the risk of developing cancer. Avoiding known carcinogens and minimizing exposure to environmental toxins could also be helpful.

For breeds that may have a genetic predisposition to rhabdomyosarcomas, it may be advisable to carefully reconsider breeding decisions. Genetic counseling and the selection of healthy breeding animals could help reduce the risk of developing these Tumors in future generations.

Outlook on current research

Rhabdomyosarcoma of the musculature in dogs is a rare, malignant tumor with skeletal muscle differentiation. This very rarity determines the research outlook: unlike more common soft tissue sarcomas, there have so far mostly been only case reports, small case series, and pathological studies. Therefore, statements on biological behavior, risk of metastasis, and optimal therapy are still significantly more uncertain than for more common tumor types. (pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov)

The most important research focus is currently more precise diagnostics. Histologically, a rhabdomyosarcoma can resemble other soft tissue sarcomas, especially if the tumor cells are poorly differentiated. Therefore, immunohistochemistry and myogenic markers such as desmin, myogenin, or MyoD1 are gaining importance. The goal is to more reliably differentiate true rhabdomyosarcomas from other mesenchymal Tumors and to classify them better biologically. (pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov)

A second focus is comparative oncology. Because rhabdomyosarcoma is also an important but heterogeneous tumor group in human medicine, research is increasingly examining the molecular commonalities and differences between dogs and humans. In the long term, this could lead to better prognostic markers and more targeted therapies. Currently, however, treatment largely relies on surgery, combined with radiation therapy or chemotherapy depending on the case. (pubmed.ncbi.nlm.nih.gov)

Overall, the outlook is cautious: the greatest progress will likely first be achieved through multicentric case collections, molecular characterization, and standardized diagnosis.

Frequently Asked Questions (FAQs)

1. What is a rhabdomyosarcoma?
Rhabdomyosarcoma is a malignant soft tissue tumor that originates from striated muscle. It belongs to the soft tissue sarcomas but behaves more aggressively than many other sarcomas and frequently metastasizes. The tumor preferentially occurs in the head, oral cavity, urinary bladder, and skeletal muscle.
2. Which dogs are affected?
Rhabdomyosarcomas occur in dogs of all ages, but more frequently in younger animals under two years of age. A clear breed predisposition does not exist, but St. Bernards and other large breeds are somewhat more commonly affected. Embryonal rhabdomyosarcoma of the urinary bladder is described in young dogs.
3. What symptoms does an affected dog show?
The Symptoms depend on the localization. Tumors on the limbs cause masses and Lameness, tumors in the oral cavity lead to eating problems, Bleeding, and bad breath. Rhabdomyosarcomas of the urinary bladder show bloody urine, Pain during urination, and incontinence.
4. How is the diagnosis made?
Fine-needle aspiration provides initial indications, but histological and immunohistochemical examination with muscle-specific markers (desmin, myoglobin, MyoD1) is conclusive. Additionally, staging is performed with CT/MRI of the affected region, lymph node, and thoracic examination to rule out metastases.
5. How is a rhabdomyosarcoma treated?
Therapy is multimodal. Surgical removal with wide safety margins is the basis. Radiation therapy is supplemented for incompletely resectable Tumors. Chemotherapy with doxorubicin, vincristine, and cyclophosphamide can be used for metastasis risk or residual tumor.
6. What is the risk of metastasis?
The risk is considerable and depends on the histological subtype. Lung metastases occur in many patients, and regional lymph nodes are also frequently affected. Careful staging and regular follow-up examinations are therefore crucial.
7. What is the prognosis for rhabdomyosarcoma?
The prognosis is generally cautious. With complete resection of small, superficial Tumors without metastases, median survival times of 12 to 24 months are possible. In cases of metastasis or incomplete resection, survival times are usually only a few months.
8. How does it differ from other soft tissue sarcomas?
Classic soft tissue sarcomas like fibrosarcoma or malignant fibrous histiocytoma grow locally invasive, but metastasize rather rarely. Rhabdomyosarcomas, however, show a significantly higher risk of metastasis and require consistent systemic therapy. Immunohistochemistry is essential for differentiation.
9. What role does aftercare play?
Due to the high risk of recurrence and metastasis, close monitoring is necessary. A clinical examination every two months, imaging of the surgical region, thoracic X-rays or CT, and lymph node examinations every three months in the first two years are recommended.
10. Is there a possibility for early detection?
General early detection is not established. Important are attention to new masses, especially in young dogs, and early biopsy of any unclear muscle mass. The earlier the diagnosis is made, the better the treatment prospects.

Literature

  • Tuohy, J. L., Byer, B. J., Royer, S., Keller, C., Nagai-Singer, M. A., Regan, D. P., & Seguin, B. (2021). Evaluation of myogenin and MyoD1 as immunohistochemical markers of canine rhabdomyosarcoma. Veterinary Pathology, 58(3), 516–526. https://doi.org/10.1177/0300985820988146
  • Caserto, B. G. (2013). A comparative review of canine and human rhabdomyosarcoma with emphasis on classification and pathogenesis. Veterinary Pathology, 50(5), 806–826. https://doi.org/10.1177/0300985813476069
  • Shi, J., Gao, R., Zhang, J., Xu, R., Jia, Q., Ma, Y., Lu, H., Zhao, K., Gao, F., & He, W. (2023). Invasive spindle-cell rhabdomyosarcoma with osteolysis in a dog: Case report and literature review. Journal of Veterinary Diagnostic Investigation, 35(2), 168–172. https://doi.org/10.1177/10406387221147319
  • Brellou, G. D., Psychas, V., & Vlemmas, I. (2017). Rhabdomyosarcomas arising from striated muscles in elderly dogs: Pathological features of 4 cases. Journal of the Hellenic Veterinary Medical Society, 64(2), 105–112. https://doi.org/10.12681/jhvms.15483
  • Ginel, P. J., Martín de las Mulas, J., Lucena, R., Millán, Y., & Novales, M. (2002). Skeletal muscle rhabdomyosarcoma in a dog. Veterinary Record, 151(24), 736–738.
  • Yhee, J. Y., Kim, D. H., Hwang, D. N., Moon, C. T., Yu, C. H., Kim, H. Y., Doster, A. R., & Sur, J. H. (2008). Hematogenous metastasis of embryonal rhabdomyosarcoma originating from skeletal muscle in a young dog. Journal of Veterinary Diagnostic Investigation, 20(2), 243–246. https://doi.org/10.1177/104063870802000219
  • Scott, E. M., Teixeira, L. B. C., Flanders, D. J., Dubielzig, R. R., & McLellan, G. J. (2016). Canine orbital rhabdomyosarcoma: A report of 18 cases. Veterinary Ophthalmology, 19(2), 130–137. https://doi.org/10.1111/vop.12270
  • Cooper, B. J., & Valentine, B. A. (2017). Tumors of muscle. In D. J. Meuten (Ed.), Tumors in domestic animals (5th ed., pp. 425–466). Wiley-Blackwell. https://doi.org/10.1002/9781119181200